<DOC>
	<DOCNO>NCT01311050</DOCNO>
	<brief_summary>A Phase I-II Trial Capecitabine ( Xeloda ) , Oxaliplatin Irinotecan Combination Bevacizumab 1st Line Treatment Metastatic Colorectal Cancer</brief_summary>
	<brief_title>A Trial Capecitabine ( Xeloda ) , Oxaliplatin Irinotecan Combination With Bevacizumab 1st Line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>A Phase I-II Trial Capecitabine ( Xeloda ) , Oxaliplatin Irinotecan Combination Bevacizumab 1st Line Treatment Metastatic Colorectal Cancer</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients diagnose Metastatic Colorectal Cancer Patients diagnosis Metastatic Colorectal Cancer</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
</DOC>